79 results about "Abnormal glucose" patented technology

Systems and methods are described providing a hepatic recycling glucose tolerance test for the diagnosis of types and subtypes of diabetes mellitus and other hyperglycemic or hypoglycemic conditions. A method is also provided for screening candidate drugs for treating various types of abnormal glucose metabolism and to monitor whether the course of treatment is effective. The method also allows the correlation of gene activity, hormone and metabolite levels with glucose flux and recycling and an assessment of the degree of hepatic insulin resistance. The method utilizes a preferably non-radioactive stable labeled glucose to asses the relative rates of carbon flow in the liver and provides a hepatic recycling constant that is a measure of the relative rate of glucose recycling. The labeled glucose may be introduced to the patient orally, intravenously or by intraperitoneal administration for the desired effect.

Systems and methods are provided for evaluating tissue for abnormal glucose uptake within a region of interest within a patient. A PET scanner obtains PET imagery including the region of interest and at least part of the liver. An SUV calculator calculates a first set of SUVs representing the region of interest and a second set SUVs representing the liver from the set of at least one PET image. A standardization component calculates a correction value as a function of the second set of SUVs and applies the correction value to either a decision threshold associated with the region of interest or the first set of SUVs. A diagnosis component compares the first set of SUVs to the decision threshold to determine if the glucose uptake within the region of interest is abnormal. A display provides the determination to a user.

Systems and methods are provided for evaluating tissue for abnormal glucose uptake within a region of interest within a patient. A PET scanner obtains PET imagery including the region of interest and at least part of the liver. An SUV calculator calculates a first set of SUVs representing the region of interest and a second set SUVs representing the liver from the set of at least one PET image. A standardization component calculates a correction value as a function of the second set of SUVs and applies the correction value to either a decision threshold associated with the region of interest or the first set of SUVs. A diagnosis component compares the first set of SUVs to the decision threshold to determine if the glucose uptake within the region of interest is abnormal. A display provides the determination to a user.

The invention relates to a PPAR (Peroxisome Proliferator-Activated Receptor) gamma / delta dual agonist shown as a general formula (I), a preparation method thereof and application of a pharmaceutical composition containing the derivative to preparation of a medicine for preventing or / and treating abnormal glucose metabolism or / and abnormal lipid metabolism diseases. The PPARgamma / delta dual agonistprovided by the invention has excellent in vivo blood glucose lowering activity and blood lipid regulation effect, and can be used for preparing medicines for preventing or / and treating metabolic syndrome related diseases including diabetes mellitus, obesity, hyperlipidemia, atherosclerosis, fatty liver and the like; the PPARgamma / delta dual agonist has a wide application prospect. The formula (I) is shown in the description.

According to a technical scheme on the first aspect, the invention provides a drug for treatment of polycystic ovary syndrome (PCOS) and abnormal glucose metabolism coexisting diseases. The drug is characterized by including the following four fatty acid components by mass: 17-22% of palmitic acid, 11-23% of hexadecenoic acid, 22-28% of 9-octadecenoic acid, 13-35% of 9, 12, 15-octatecatrienoic acid, and the balance pharmaceutically acceptable additives or excipients. The components are mixed according to compatibility to be prepared into soft capsules and other oral preparations, so that the insulin receptor substrate (IRS) protein level can be effectively reduced so as to inhibit the glucose way, the insulin receptor active time can be increased and the insulin level can be enhanced, and the insulin sensitivity is increased so as to facilitate the reduction of insulin resistance degree. Thus, the drug can have the functions of improving and recuperating ovary ovulatory dysfunction, i.e. PCOS and abnormal glucose metabolism diseases. Compared with other drugs, the drug has simple components, and belongs to highly effective, safety, and simplified drugs.

The invention discloses a medicine for treating diabetes mellitus. The medicine is made by the following raw materials: balsam pear slices 30g, sophorae flavescentis radix 9g, coptis chinensis 30g, anemarrhenae rhizome 30g, spina date seed 15g, zingiberis rhizoma tostum 6g, monascus 3g, tangerine peel 9g, rhubarb 2g and persicae semen 6g. The invention achieves repeatable affirmation effect through the clinical test for treating 2-type diabetes mellitus by the heat clearing and cloud dropping method, which can improve a 2-type diabetes mellitus model rat abnormal glucose metabolism by means of the obvious improvement of insulin resistance and islet cell function. The invention has great significance on alleviating fatty liver and maintaining normal blood lipid.

The invention relates to a scanning method and device for multi-modal medical equipment. The method comprises the steps of obtaining a first scanning image which is a tomography image with the anatomical structure information of a scanned object; acquiring the first PET scanning data of the scanned object, and reconstructing a first PET scanning image according to the first PET scanning data; identifying an abnormal glucose metabolism point in the first PET scanning image; recommending a medical scanning protocol according to the abnormal glucose metabolism point information; and performing medical scanning on the scanned object according to the medical scanning protocol. According to the method, the abnormal point in the PET scanning image is automatically identified, and the medical scanning protocol is intelligently recommended based on the position with glucose metabolism abnormality, so that the problems of relatively higher labor cost and relatively lower efficiency in an abnormal point discovery or confirmation process in related technologies are solved.

In one aspect, the invention relates to methods for treating a disease or condition associated with abnormal glucose metabolism. In another aspect, the invention relates to a method for reducing incidence or progression of insulin-dependent diabetes mellitus. The methods include orally administering to a mammal in need thereof an effective amount of a composition, which includes a naturally occurring material derived from eggshell, eggshell membrane, or a combination thereof.

The invention which relates to a crude tea composition for controlling abnormal glucose tolerance belongs to the technical field of food compositions with both functions of drugs and foods. The crude tea composition is prepared from the following raw materials, by weight, 6-10 parts of Dafo Longjing tea, 2-10 parts of loquat leaf, 2-10 parts of mulberry leaf, 2-10 parts of lotus leaf, and 2-10 parts of honeysuckle flower. The crude tea composition for controlling the abnormal glucose tolerance, which has a reasonable ratio and has the efficacies of heat clearing and blood cooling, stomach harmonization and phlegm and moisture reduction, thirst quenching, glucose and lipid lowering and the like is suitable for patients with abnormal glucose tolerances, and is especially suitable for obese people. The cure rate of the abnormal glucose tolerance treated by the crude tea composition of the invention can achieve more than 90%; and compared with costs of present drugs, the cost of the crudetea composition of the invention is reduced by more than 10%.

The invention provides an application of bergamottin in preparation of medicines for preventing and treating diabetes and preparation of functional foods or health care products for preventing and treating diabetes. The bergamottin has the chemical formula of C21H22O4 and the relative molecular mass of 338.4. Studies prove that the bergamottin shows significant glucose consumption activity in human liver cancer HepG2 cells and has good concentration dependence, the action concentration is far lower than that of a positive medicine, namely metformin, and the efficacy is better than that of metformin. The bergamottin can significantly reduce blood glucose of diabetic KK-Ay mice in diabetic KK-Ay mouse bodies and increase glucose tolerance and insulin sensitivity. The studies about hypoglycemic activity of the bergamottin on intracellular level and in-vivo level show that the bergamottin shows significant hypoglycemic activity, can increase the glucose tolerance and insulin sensitivity and can be used as a treatment medicine or functional food or health care product for preventing and treating diseases related to abnormal glucose metabolism.

In one aspect, the invention relates to methods for treating a disease or condition associated with abnormal glucose metabolism. In another aspect, the invention relates to a method for reducing incidence or progression of insulin-dependent diabetes mellitus. The methods include orally administering to a mammal in need thereof an effective amount of a composition, which includes a naturally occurring material derived from eggshell, eggshell membrane, or a combination thereof.

The present invention relates to compounds of formula (I); compositions comprising the compounds, and methods of using the compounds to treat or prevent pain, diabetes, a diabetic complication, impaired glucose tolerance (IGT) or impaired fasting glucose (IGT) in a patient.

The invention discloses a compound with PPAR multiple agonist activities and a preparation method and application thereof. The compound has the chemical structure as shown in the formula I. Research results show that the compound adopting the formula I can remarkably improve the transcriptional activities of PPAR alpha, beta and gamma, has the multiple agonist activities of PPAR alpha, beta band gamma, is expected to serve as an active ingredient to be used for preparing a drug or health food for preventing and / or treating metabolic syndromes, and is particularly expected to be used for preparing a drug or health food for preventing and / or treating abnormal glucose metabolism and / or abnormal lipids metabolism diseases. The compound has a wide application prospect and a remarkable medicinal value.

The invention discloses a PPAR (peroxisome proliferator-activated receptor) alpha-gamma dual agonist and an application thereof. The PPAR alpha-gamma dual agonist contains an effective quantity of a derivative represented by the formula I or the formula II in the description and a pharmaceutically acceptable salt of the derivative, wherein definition of each substituent group is as claimed in theclaims and the description. Experiments prove that the compound represented as the formula I or the formula II can remarkably improve PPAR alpha-gamma transcriptional activity and mRNA level of related target genes, has PPAR alpha-gamma dual agonist activity and can be taken as an effective component of the PPAR alpha-gamma dual agonist. The PPAR alpha-gamma dual agonist can be applied to preparation of drugs and healthy food for preventing or / and treating metabolic syndromes, particularly can be applied to preparation of drugs and healthy food for preventing or / and treating abnormal glucose metabolism or / and abnormal lipids metabolism diseases, and has broad application prospect.

The invention discloses a Japanese galangal flower extract for improving sugar tolerance and a usage of the Japanese galangal flower extract. The extract is extracted from the raw material Japanese galangal flower, wherein the Japanese galangal flower is flower of Alpinia japonica Miq of the Alpinia genus of the ginger family. The Japanese galangal flower extract is capable of obviously improving sugar tolerance and decreasing fasting or postprandial blood glucose levels of the patients, so that the Japanese galangal flower extract plays a significant regulatory role in the blood glucose level of the patient with abnormal glucose tolerance, hyperglycemia or diabetes; thus, the Japanese galangal flower extract can be developed into drugs, health foods or functional foods for the patients with abnormal glucose tolerances. The Japanese galangal flower extract has relatively wide applicable crowd.

The present invention relates to Compounds of Formula (I), compositions comprising the compounds, and methods of using the compounds to treat or prevent pain, diabetes, a diabetic complication, impaired glucose tolerance (IGT) or impaired fasting glucose (IFG) in a patient.

The invention provides an application of citrus changshanensis extract in preparing sugar-reducing functional foods, health-care products or sugar-reducing medicines. The citrus changshanensis extract comprises an oil-cell layer, a white-skin layer and a bag-coating extract, so that the fasting blood glucose and the serum glucose of a C57BL / 6 mouse with diabetes can be obviously reduced in vivo, the glucose tolerance can be increased and the insulin resistance can be reduced. The citrus changshanensis extract can be used for preventing and treating diseases related to abnormal glucose metabolism as a functional food, a health-care product or a preventing and treating medicine.

Compounds having an excellent hypoglycemic effect and β cell- or pancreas-preserving effects or pharmaceutically acceptable salts thereof, and a pharmaceutical composition having an excellent therapeutic effect and / or prophylactic effect on type 1 diabetes, type 2 diabetes, and the like, which cause hyperglycemia due to abnormal glucose metabolism. A compound represented by general formula (I), or a pharmaceutically acceptable salt thereof, is disclosed.

The invention discloses an application of notoginsenoside Ft1 and particularly provides the application of notoginsenoside Ft1 to preparation of a TGR5 agonist as an active ingredient. Studies prove that notoginsenoside Ft1 has a remarkable TGR5 agonist activity and can serve as an effective ingredient of the TGR5 agonist. Besides, a C57BL / 6J mouse is taken as a study object, the studies prove that notoginsenoside Ft1 can effectively improve lipid metabolism, glycometabolism and insulin sensitivity of the mouse when used as the TGR5 agonist, can be applied to preparation of drugs and health food for preventing and / or treating metabolic diseases and is particularly expected to be applied to preparation of the drugs or the health food for preventing and / or treating abnormal glucose metabolism, abnormal lipid metabolism or / and abnormal insulin sensitivity.

The invention discloses new application of a p53 gene, and particularly relates to application of the P53 gene in preparation of a drug for treatment of glucose metabolism abnormality diseases, belonging to the field of bio-pharmaceuticals. In the embodiment, a db / db rat is used as a research object to prove good hypoglycemic effects of the p53 gene. Moreover, six patients with Type II diabetes are treated, and the same significant curative effect can be achieved. In combination with results of study at the diabetes pathogenesis gene level in recent years and use of the p53 gene as a controlling gene for a key abnormal gene in the body, correction of abnormal glucose metabolism can be realized by regulating a gene encoding method corresponding to a relevant regulatory factor in the process of abnormal glucose metabolism. The problem of genetic treatment of glucose metabolism abnormality diseases can be solved, and the p53 gene has broad application prospects in treatment of diabetes.

Systems and methods are provided for evaluating tissue for abnormal glucose uptake within a region of interest within a patient. A PET scanner obtains PET imagery including the region of interest and at least part of the liver. An SUV calculator calculates a first set of SUVs representing the region of interest and a second set SUVs representing the liver from the set of at least one PET image. A standardization component calculates a correction value as a function of the second set of SUVs and applies the correction value to either a decision threshold associated with the region of interest or the first set of SUVs. A diagnosis component compares the first set of SUVs to the decision threshold to determine if the glucose uptake within the region of interest is abnormal. A display provides the determination to a user.

The invention provides an application of nucleolin in the preparation of drugs for improving glucose metabolism disorders, regulating the activity of glycogen synthase and regulating the phosphorylation level of glycogen synthase. According to the invention, it is confirmed that nucleolin is a glucose metabolism-related molecule by establishing a model of high fat diet-induced glucose metabolism disorders and a mouse model of nucleolin overexpression, and it is found that nucleolin can improve the activity of glycogen synthase by inhibiting phosphorylation of glycogen synthase in the liver, thereby improving glycogen synthesis ability of liver tissues, enhancing glucose tolerance dose and insulin sensitivity of the body and participating in the regulation of body glucose homeostasis and the treatment of glucose metabolism disorders; and the up-regulation of nucleolin expression has an effect of resisting abnormal glucose metabolism and insulin resistance. The invention provides a new target for the prevention and treatment of type 2 diabetes mellitus and prediabetes, and nucleolin can be used for studies on the preparation of drugs for early intervention of type 2 diabetes mellitusand delaying the progress of the course of disease.

The purpose of the present invention is to provide a novel therapeutic agent or a novel prophylactic agent for diseases associated with abnormal glucose metabolism. The present invention is a therapeutic agent or a prophylactic agent for diseases associated with abnormal glucose metabolism, which comprises a 2-phenylthiazole compound represented by formula (I) or a pharmaceutically acceptable salt thereof as an active ingredient.

The invention discloses the application of a traditional Chinese medicines formula in preparing drugs treating metabolic syndrome, in particular to the application of traditional Chinese medicines formula formed by three kinds of crude drugs comprising astragalus, semen litchi and lotus leaf, extract powder or the active ingredients in preparing the drugs and to the application in preparing drugs improving at least one symptom of insulin resistance, abnormal glucose metabolism, hypertension, obesity and lipids disorder. The application of a traditional Chinese medicines formula has the advantages of playing effective compatible role of the traditional Chinese medicine ingredient, not only being used as preparing drugs treating each kind of disease of metabolic syndrome, but also providing technical base for research and development aiming at the integrity of the metabolic syndrome and complicating disease and providing safe, effective and economic technical base for nationally preventing metabolic syndrome.

A composition for prevention and treatment of metabolic syndromes is composed of radix astragali preparata, rhizoma polygonati, mulberry fruits, yam, fructus crataegi, lotus leaves, cassia seeds, phaseolus calcaratus, poria cocos, endothelium corneum gigeriae galli, fructus amomi, dandelions and the like. It is verified that the composition has the functions of relieving and preventing the metabolic syndromes such as abdominal obesity, dyslipidemia and abnormal glucose metabolism.

The invention discloses a pharmaceutical composition for treating diabetes. The active ingredients of the pharmaceutical composition comprise (by weight parts) Momordica charantia 25-35, Rhizoma Coptidis 25-35, Monas cuspurpureus 2-4, processed Zingiber officinale and Radix Et Rhizoma Rhei 1-3. The pharmaceutical composition can reduce insulin resistance and restore the functions of the islet cells to greatly improve abnormal glucose metabolism, is significant in relieving fatty liver and maintaining normal blood lipid level, and is clinically used for the treatment of diabetes.

The invention relates to the technical field of medicines, in particular to a Tmem52 protein for regulating glycolipid metabolism, a coding gene and application of the Tmem52 protein. The amino acid sequence of the Tmem52 protein disclosed by the invention is as shown in SEQ ID NO. 1. According to the invention, C57BL6 / n wild mice fed with high-fat feed are taken as research objects, and the weight of the mice can be obviously reduced by utilizing the Tmem52 protein preparation provided by the invention, so that the Tmem52 protein provided by the invention can be used for treating obesity and related diseases by regulating abnormal glucose and lipid metabolism.